Book review: Acute respiratory distress syndrome - a comprehensive clinical approach

J. Goodall,C. Gwinnutt

DOI: https://doi.org/10.1177/146040860000200210

2000-04-01

Thorax

Abstract:

What problem does this paper attempt to address?

Acute lung injury and the acute respiratory distress syndrome: a clinical review

Arthur P Wheeler,Gordon R Bernard

DOI: https://doi.org/10.1016/S0140-6736(07)60604-7

2007-05-05

Abstract:Acute respiratory distress syndrome and acute lung injury are well defined and readily recognised clinical disorders caused by many clinical insults to the lung or because of predispositions to lung injury. That this process is common in intensive care is well established. The mainstay of treatment for this disorder is provision of excellent supportive care since these patients are critically ill and frequently have coexisting conditions including sepsis and multiple organ failure. Refinements in ventilator and fluid management supported by data from prospective randomised trials have increased the methods available to effectively manage this disorder.
Acute respiratory distress syndrome: A review of ARDS across the life course

Caleb Cave,Dannielle Samano,Abhineet M Sharma,John Dickinson,Jeffrey Salomon,Sidharth Mahapatra

DOI: https://doi.org/10.1177/10815589241270612

2024-08-28

Abstract:Acute respiratory distress syndrome (ARDS) is a multifactorial, inflammatory lung disease with significant morbidity and mortality that predominantly requires supportive care in its management. Although initially described in adult patients, the diagnostic definitions for ARDS have evolved over time to accurately describe this disease process in pediatric and, more recently, neonatal patients. The management of ARDS in each age demographic has converged in the application of lung-protective ventilatory strategies to mitigate the primary disease process and prevent its exacerbation by limiting ventilator-induced lung injury. However, differences arise in the preferred ventilatory strategies or adjunctive pulmonary therapies used to mitigate each type of ARDS. In this review, we compare and contrast the epidemiology, common etiologies, pathophysiology, diagnostic criteria, and outcomes of ARDS across the lifespan. Additionally, we discuss in detail the different management strategies used for each subtype of ARDS and spotlight how these strategies were applied to mitigate poor outcomes during the COVID-19 pandemic. This review is geared toward both clinicians and clinician-scientists as it not only summarizes the latest information on disease pathogenesis and patient management in ARDS across the lifespan but also highlights knowledge gaps for further investigative efforts. We conclude by projecting how future studies can fill these gaps in research and what improvements may be envisioned in the management of NARDS and PARDS based on the current breadth of literature on adult ARDS treatment strategies.
Acute Respiratory Distress Syndrome: Bench‐to‐Bedside Approaches to Improve Drug Development

Musaddique Hussain,Chengyun Xu,Mashaal Ahmad,Abdul Majeed,Meiping Lu,Xiling Wu,Lanfang Tang,Ximei Wu

DOI: https://doi.org/10.1002/cpt.1034

2018-01-01

Abstract:Despite 50 years of extensive research, no definite drug is currently available to treat acute respiratory distress syndrome (ARDS), and the supportive therapies remain the mainstay of treatment. To improve drug development for ARDS, researchers need to deeply analyze the “omics” approaches, reevaluate the suitable therapeutic targets, resolve the problems of inadequate animal modeling, develop the strategies to reduce the heterogeneity, and reconsider new therapeutic and analytical approaches for better designs of clinical trials.
The Acute Respiratory Distress Syndrome in 2013

Michael A Matthay,Yuanlin Song,Chunxue Bai,Kirk D Jones

DOI: https://doi.org/10.1186/2213-0802-1-10

2013-01-01

Translational Respiratory Medicine

Abstract:Acute lung injury and the acute respiratory distress syndrome are major causes of morbidity and mortality in critically ill patients. This review focuses on new developments in definitions, epidemiology, clinical and basic research, and promising new directions in treatment. There is new information about the potential contribution of environmental factors, especially exposure to cigarette smoke. Pathologic findings in ARDS have been limited to case reports of open lung biopsies and post-mortem studies but there is some new information from a recent pathology study relative to the frequency of diffuse alveolar damage and the severity of arterial hypoxemia. Further, therapy with lung-protective ventilation and fluid conservative protocol has improved outcomes, but several new trials are in progress to test several promising strategies.
Acute Respiratory Distress Syndrome: Bench-to-Bedside Approaches to Improve Drug Development.

Musaddique Hussain,Chengyun Xu,Mashaal Ahmad,Abdul Majeed,Meiping Lu,Xiling Wu,Lanfang Tang,Ximei Wu

DOI: https://doi.org/10.1002/cpt.1034

2018-01-01

Clinical Pharmacology & Therapeutics

Abstract:Despite 50 years of extensive research, no definite drug is currently available to treat acute respiratory distress syndrome (ARDS), and the supportive therapies remain the mainstay of treatment. To improve drug development for ARDS, researchers need to deeply analyze the omics approaches, reevaluate the suitable therapeutic targets, resolve the problems of inadequate animal modeling, develop the strategies to reduce the heterogeneity, and reconsider new therapeutic and analytical approaches for better designs of clinical trials.
Towards Simulation-Based Similarity of End User Browsing Processes

Sudhir Agarwal,M. Junghans

DOI: https://doi.org/10.1007/978-3-642-39200-9_19

2013-07-08

Abstract:
[Consensus conference: home intravenous antibiotic treatment for cystic fibrosis. The Sira Carrasco Foundation. 26 April 2002].

A. Salcedo,R. Girón,B. Beltrán,Ana Meca Martínez,Luis Máiz,L. Suárez,Fundación Sira Carrasco

2003-10-01

Archivos de Bronconeumologia

Abstract:Cystic fibrosis (CF) is the most common terminal genetic illness amongst Caucasians. The median survival age has increased more dramatically over the last 25 years than for any other chronic illness,1 reaching 33.4 years by 2001, according to the American Cystic Fibrosis Foundation.2 The improvement in survival of CF patients has meant that the number of CF patients over the age of 18 years has increased from 8% in 1970 to 39.5% in 2001, in the USA.2 Exacerbations and hospitalization increase after the first ten years of CF patients’ lives, so patients and their families are familiar with many treatment effects and there is no reason why treatment should not be carried out in the patient’s home. According to data from the American Cystic Fibrosis Foundation for 2001, cultures of respiratory secretions were positive for Pseudomonas aeruginosa in 58.8% of cases, Staphylococcus aureus in 48%, Burkholderia cepacia in 3.1%, and Stenotrophomonas maltophilia in 8.4%. The only data available for Spain were collected in 1997 by the Federación Española contra la Fibrosis Quística. Only 15 CF units out of the whole country participated in this registry, which included a total of 823 patients with a median age of 15.1 years. Microbiological findings for these patients revealed that 37.06% were colonized with P aeruginosa, 35.60% with S aureus, 12.88% with Haemophilus influenzae, 2.79% with S malthophilia, 1.94% with B. cepacia, and 15.9% were not colonized by any germ. Intravenous (IV) antibiotic treatment is normally given to patients with moderate to severe respiratory exacerbations, or in cycles for patients chronically colonized by P aeruginosa, mucoid phenotype. In the latter case, adverse effects such as allergic reactions to antibiotics or increased bacterial resistance to antibiotics are more common. Nearly 2.5 times more adults than children currently elect home intravenous antibiotic treatment (HIVAT). According to data from the American Cystic Fibrosis Foundation, HIVAT use increased from 12% in 1990 to 20.3% in 2001.2 In order to discover the current situation of HIVAT for CF patients in Spain, the Sira Carrasco Foundation in aid of CF organized a consensus conference for specialists involved in CF, in Madrid on April 26, 2002. Two months prior to the conference, a letter was sent to all the CF units in Spain, saying that on the web page of the Sira Carrasco Foundation (www.fundacionfibrosisquistica.org) there was a questionnaire on HIVAT to be filled in and sent by Internet or post. The data from the questionnaires was statistically processed and the results discussed and consensus reached at the conference. Twenty CF units participated; among them they control 1230 patients, 740 younger than 18 years of age and 490 older. This document summarizes the consensus reached on different questions related to HIVAT and the resulting recommendations.
ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies

Giacomo Grasselli,Carolyn S Calfee,Luigi Camporota,Daniele Poole,Marcelo B P Amato,Massimo Antonelli,Yaseen M Arabi,Francesca Baroncelli,Jeremy R Beitler,Giacomo Bellani,Geoff Bellingan,Bronagh Blackwood,Lieuwe D J Bos,Laurent Brochard,Daniel Brodie,Karen E A Burns,Alain Combes,Sonia D'Arrigo,Daniel De Backer,Alexandre Demoule,Sharon Einav,Eddy Fan,Niall D Ferguson,Jean-Pierre Frat,Luciano Gattinoni,Claude Guérin,Margaret S Herridge,Carol Hodgson,Catherine L Hough,Samir Jaber,Nicole P Juffermans,Christian Karagiannidis,Jozef Kesecioglu,Arthur Kwizera,John G Laffey,Jordi Mancebo,Michael A Matthay,Daniel F McAuley,Alain Mercat,Nuala J Meyer,Marc Moss,Laveena Munshi,Sheila N Myatra,Michelle Ng Gong,Laurent Papazian,Bhakti K Patel,Mariangela Pellegrini,Anders Perner,Antonio Pesenti,Lise Piquilloud,Haibo Qiu,Marco V Ranieri,Elisabeth Riviello,Arthur S Slutsky,Renee D Stapleton,Charlotte Summers,Taylor B Thompson,Carmen S Valente Barbas,Jesús Villar,Lorraine B Ware,Björn Weiss,Fernando G Zampieri,Elie Azoulay,Maurizio Cecconi,European Society of Intensive Care Medicine Taskforce on ARDS

DOI: https://doi.org/10.1007/s00134-023-07050-7

Abstract:The aim of these guidelines is to update the 2017 clinical practice guideline (CPG) of the European Society of Intensive Care Medicine (ESICM). The scope of this CPG is limited to adult patients and to non-pharmacological respiratory support strategies across different aspects of acute respiratory distress syndrome (ARDS), including ARDS due to coronavirus disease 2019 (COVID-19). These guidelines were formulated by an international panel of clinical experts, one methodologist and patients' representatives on behalf of the ESICM. The review was conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement recommendations. We followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess the certainty of evidence and grade recommendations and the quality of reporting of each study based on the EQUATOR (Enhancing the QUAlity and Transparency Of health Research) network guidelines. The CPG addressed 21 questions and formulates 21 recommendations on the following domains: (1) definition; (2) phenotyping, and respiratory support strategies including (3) high-flow nasal cannula oxygen (HFNO); (4) non-invasive ventilation (NIV); (5) tidal volume setting; (6) positive end-expiratory pressure (PEEP) and recruitment maneuvers (RM); (7) prone positioning; (8) neuromuscular blockade, and (9) extracorporeal life support (ECLS). In addition, the CPG includes expert opinion on clinical practice and identifies the areas of future research.
Acute Respiratory Distress Syndrome and COVID-19: A Literature Review

Musaddique Hussain,Shahzada Khurram Syed,Mobeen Fatima,Saira Shaukat,Malik Saadullah,Ali M Alqahtani,Taha Alqahtani,Talha Bin Emran,Ali H Alamri,Muhammad Qasim Barkat,Ximei Wu

DOI: https://doi.org/10.2147/JIR.S334043

IF: 4.5

2021-01-01

Journal of Inflammation Research

Abstract:Acute respiratory distress syndrome (ARDS) is an overwhelming inflammatory disorder of the lung due to direct and indirect insults to the lungs. ARDS is characterized by increased vascular permeability, protein-rich edema, diffuse alveolar infiltrate, and loss of aerated lung tissue, leading to decreased lung compliance, tachypnea, and severe hypoxemia. COVID-19 is generally associated with ARDS, and it has gained prime importance since it started. The mortality rate is alarmingly high in COVID-19-related ARDS patients regardless of advances in mechanical ventilation. Several pharmacological agents, including corticosteroids, nitric oxide, neuromuscular blocker, anti-TNF, statins, and exogenous surfactant, have been studied and some are under investigation, like ketoconazole, lisofylline, N-acetylcysteine, prostaglandins, prostacyclin, and fish oil. The purpose of this review is to appraise the understanding of the pathophysiology of ARDS, biomarkers, and clinical trials of of ARDS and COVID-19-related ARDS.
An Overview on Mechanistic Insights and Clinical Benefit

Jinquan Zhang,Peng Ge,Jie Liu,Yalan Luo,Haoya Guo,Guixin Zhang,Caiming Xu,Hailong Chen

DOI: https://doi.org/10.3390/ijms241512138

IF: 5.6

2023-07-29

International Journal of Molecular Sciences

Abstract:Acute lung injury/acute respiratory distress syndrome (ALI/ARDS), triggered by various pathogenic factors inside and outside the lungs, leads to diffuse lung injury and can result in respiratory failure and death, which are typical clinical critical emergencies. Severe acute pancreatitis (SAP), which has a poor clinical prognosis, is one of the most common diseases that induces ARDS. When SAP causes the body to produce a storm of inflammatory factors and even causes sepsis, clinicians will face a two-way choice between anti-inflammatory and anti-infection objectives while considering the damaged intestinal barrier and respiratory failure, which undoubtedly increases the difficulty of the diagnosis and treatment of SAP-ALI/ARDS. For a long time, many studies have been devoted to applying glucocorticoids (GCs) to control the inflammatory response and prevent and treat sepsis and ALI/ARDS. However, the specific mechanism is not precise, the clinical efficacy is uneven, and the corresponding side effects are endless. This review discusses the mechanism of action, current clinical application status, effectiveness assessment, and side effects of GCs in the treatment of ALI/ARDS (especially the subtype caused by SAP).

biochemistry & molecular biology,chemistry, multidisciplinary
Lymphocytic hypophysitis with normal pituitary function mimicking a pituitary adenoma: a case report and review of literature.

M. Rumana,A. Kirmani,N. Khursheed,S. Besina,M. Khalil

DOI: https://doi.org/10.5414/NPP29026

IF: 1.136

Clinical Neuropathology

Abstract:Lymphocytic hypophysitis (LYH) is a rare autoimmune inflammatory disorder of the pituitary gland usually affecting young women, often in pregnancy or post partum period. It is rare in non-pregnant females and in men. Patients present with symptoms of an expanding pituitary mass and/or varying degrees of pituitary dysfunction. We, hereby report a case of lymphocytic hypophysitis in a 28-year-old non-pregnant female who presented with clinical and radiological features of a pituitary tumor with normal pituitary hormones which on histopathological examination revealed features of lymphocytic hypophysitis. The case is presented here for its rarity and its unique presentation as an expanding pituitary mass with normal pituitary function. Peculiar clinical, radiological and histopathological features of this uncommon entity are discussed.
Early identification and diagnosis, pathophysiology, and treatment of sepsis-related acute lung injury: a narrative review

Jie Zhang,Wenxiao Yan,Yansong Dong,Xinye Luo,Hua Miao,Talaibaike Maimaijuma,Xianggui Xu,Haiyan Jiang,Zhongwei Huang,Lei Qi,Guiwen Liang

DOI: https://doi.org/10.21037/jtd-24-1191

2024-08-31

Abstract:Background and objective: Sepsis is a life-threatening organ dysfunction, and the most common and vulnerable organ is the lungs, with sepsis-related acute respiratory distress syndrome (ARDS) increasing mortality. In recent years, an increasing number of studies have improved our understanding of sepsis-related ARDS in terms of epidemiology, risk factors, pathophysiology, prognosis, and other aspects, as well as our ability to prevent, detect, and treat sepsis-related ARDS. However, sepsis-related lung injury remains an important issue and clinical burden. Therefore, a literature review was conducted on sepsis-related lung injury in order to further guide clinical practice in reducing the acute and chronic consequences of this condition. Methods: This study conducted a search of the MEDLINE and PubMed databases, among others for literature published from 1991 to 2023 using the following keywords: definition of sepsis, acute lung injury, sepsis-related acute lung injury, epidemiology, risk factors, early diagnosis of sepsis-related acute lung injury, sepsis, ARDS, pathology and physiology, inflammatory imbalance caused by sepsis, congenital immune response, and treatment. Key content and findings: This review explored the risk factors of sepsis, sepsis-related ARDS, early screening and diagnosis, pathophysiology, and treatment and found that in view of the high mortality rate of ARDS associated with sepsis. In response to the high mortality rate of sepsis-related ARDS, some progress has been made, such as rapid identification of sepsis and effective antibiotic treatment, early fluid resuscitation, lung-protective ventilation, etc. Conclusions: Sepsis remains a common and challenging critical illness to cure. In response to the high mortality rate of sepsis-related ARDS, progress has been made in rapid sepsis identification, effective antibiotic treatment, early fluid resuscitation, and lung-protective ventilation. However, further research is needed regarding long-term effects such as lung recruitment, prone ventilation, and the application of neuromuscular blocking agents and extracorporeal membrane oxygenation.
Definitions of Acute Respiratory Distress Syndrome: Present Recommendations and Challenges

Dilip Jayasimhan,Michael A Matthay

DOI: https://doi.org/10.1016/j.ccm.2024.08.001

Abstract:Acute respiratory distress syndrome (ARDS) is an acute inflammatory process resulting in diffuse lung injury precipitated by an underlying risk factor. However, current definitions may pose barriers to the accurate diagnosis of this syndrome. These include changes in risk factors and associated disease evolution of ARDS, changes in contemporary clinical practice, and access to diagnostic tools required to diagnose ARDS in resource-limited settings. A consensus conference has proposed changes for an expanded global definition of ARDS. In this review article, we review challenges in defining ARDS and present recommendations of the global definition of ARDS.
Share First, Save Later: Performance of Self through Snapchat Stories

Sarah McRoberts,Haiwei Ma,Andrew Hall,S. Yarosh

DOI: https://doi.org/10.1145/3025453.3025771

2017-05-02

Abstract:As the third most popular social network among millennials, Snapchat is well known for its picture and video messaging system that deletes content after it is viewed. However, the Stories feature of Snapchat offers a different perspective of ephemeral content sharing, with pictures and videos that are available for friends to watch an unlimited number of times for 24 hours. We conduct-ed an in-depth qualitative investigation by interviewing 18 participants and reviewing 14 days of their Stories posts. We identify five themes focused on how participants perceive and use the Stories feature, and apply a Goffmanesque metaphor to our analysis. We relate the Stories medium to other research on self-presentation and identity curation in social media.
The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum.

R. Ulevitch,A. Johnston

DOI: https://doi.org/10.1172/JCI109252

IF: 19.456

1978-12-01

Journal of Clinical Investigation

Abstract:Normal rabbit serum reduces the buoyant density of lipopolysaccharide (LPS) from Escherichia coli 0111:B4 (d = 1.44 g/cm3) and Salmonella minnesota R595 (d = 1.38 g/cm3) to a value less than g/cm3. This density shift is associated with the inhibition of a number of endotoxic activities of the LPS; namely, the pyrogenic activity, the ability to produce an immediate neutropenia in rabbits, lethality in adrenalectomized mice, and anticomplementary activity. A qualitatively similar change in buoyant density was observed to occur after intravenous injection of the LPS into rabbits. Preliminary evidence suggests that the density shift does not occur as a result of the degradation of the glycolipid backbone of the LPS. These data suggest that the interactions of LPS with plasma (or serum) components leading to reduction in buoyant density may account for a major pathway of LPS detoxification.
Lung- and Diaphragm-protective Ventilation in Acute Respiratory Distress Syndrome: Rationale and Challenges.

E. Goligher,T. Schepens

DOI: https://doi.org/10.1097/ALN.0000000000002605

IF: 8.986

2019-04-01

Anesthesiology

Abstract:A novel approach to ventilation aims to be both lung- and diaphragm-protective. This strategy integrates concerns over excessive lung stress during spontaneous breathing while avoiding both insufficient and excessive inspiratory effort.

Medicine
Management of the acute respiratory distress syndrome

Steven A Conrad,Akhil Bidani

DOI: https://doi.org/10.1016/s1052-3359(02)00012-1

Abstract:Significant advances have occurred in the knowledge of the pathogenesis of ARDS. It is now recognized that ARDS is a manifestation of a diffuse process that results from a complicated cascade of events following an initial insult or injury. Mechanical ventilation and PEEP are still important components of supportive therapy. To avoid ventilator-associated lung injury there is emphasis on targeting ventilator management based on measurement of pulmonary mechanics. For those with resistant hypoxia and severe pulmonary hypertension adjunctive modalities, such as prone positioning and low-dose iNO, may provide important benefit. Alternative modes of supporting gas exchange, such as with partial liquid ventilation and extracorporeal gas-exchange, may serve as rescue therapies. Advances in cell and molecular biology have contributed to a better understanding of the role of inflammatory cells and mediators that contribute to the acute lung injury and the pathophysiology of the syndrome that manifests as ARDS. Based on this new understanding, the potential targets for intervention to ameliorate the systemic inflammatory response have proliferated. Examples include the cytokine network and its receptors, antioxidants, and endothelins. Apart from the challenge of testing these agents in experimental models, it seems likely that determination of the optimum combination of agents will become an equally important endeavor. A particular challenge is to develop better methods of predicting which of the many at-risk patients will go on to full-blown ARDS and MODS, thereby targeting subgroups of patients most likely to benefit from anti-inflammatory therapies. Similarly, the adverse effects of immunosuppressive therapy may be diminished by improved, perhaps molecular, techniques to detect microbial pathogens and permit differentiation between Systemic inflammatory response syndrome and sepsis.
An Update on Management of Adult Patients with Acute Respiratory Distress Syndrome: An Official American Thoracic Society Clinical Practice Guideline

Nida Qadir,Sarina Sahetya,Laveena Munshi,Charlotte Summers,Darryl Abrams,Jeremy Beitler,Giacomo Bellani,Roy G Brower,Lisa Burry,Jen-Ting Chen,Carol Hodgson,Catherine L Hough,Francois Lamontagne,Anica Law,Laurent Papazian,Tai Pham,Eileen Rubin,Matthew Siuba,Irene Telias,Setu Patolia,Dipayan Chaudhuri,Allan Walkey,Bram Rochwerg,Eddy Fan

DOI: https://doi.org/10.1164/rccm.202311-2011ST

2024-01-01

Abstract:Background: This document updates previously published Clinical Practice Guidelines for the management of patients with acute respiratory distress syndrome (ARDS), incorporating new evidence addressing the use of corticosteroids, venovenous extracorporeal membrane oxygenation, neuromuscular blocking agents, and positive end-expiratory pressure (PEEP). Methods: We summarized evidence addressing four "PICO questions" (patient, intervention, comparison, and outcome). A multidisciplinary panel with expertise in ARDS used the Grading of Recommendations, Assessment, Development, and Evaluation framework to develop clinical recommendations. Results: We suggest the use of: 1) corticosteroids for patients with ARDS (conditional recommendation, moderate certainty of evidence), 2) venovenous extracorporeal membrane oxygenation in selected patients with severe ARDS (conditional recommendation, low certainty of evidence), 3) neuromuscular blockers in patients with early severe ARDS (conditional recommendation, low certainty of evidence), and 4) higher PEEP without lung recruitment maneuvers as opposed to lower PEEP in patients with moderate to severe ARDS (conditional recommendation, low to moderate certainty), and 5) we recommend against using prolonged lung recruitment maneuvers in patients with moderate to severe ARDS (strong recommendation, moderate certainty). Conclusions: We provide updated evidence-based recommendations for the management of ARDS. Individual patient and illness characteristics should be factored into clinical decision making and implementation of these recommendations while additional evidence is generated from much-needed clinical trials.
Monitoring Patient Respiratory Effort During Mechanical Ventilation: Lung and Diaphragm-Protective Ventilation

Michele Bertoni,Savino Spadaro,Ewan C. Goligher

DOI: https://doi.org/10.1186/s13054-020-2777-y

IF: 15.1

2020-03-24

Critical Care

Abstract:This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency Medicine 2020. Other selected articles can be found online at <a href="https://www.biomedcentral.com/collections/annualupdate2020">https://www.biomedcentral.com/collections/annualupdate2020</a>. Further information about the Annual Update in Intensive Care and Emergency Medicine is available from <a href="http://www.springer.com/series/8901">http://www.springer.com/series/8901</a>.

critical care medicine
Lung Ultrasound in Critical Care and Emergency Medicine: Clinical Review

Eduardo Rocca,Christian Zanza,Yaroslava Longhitano,Fabio Piccolella,Tatsiana Romenskaya,Fabrizio Racca,Gabriele Savioli,Angela Saviano,Andrea Piccioni,Silvia Mongodi

DOI: https://doi.org/10.3390/arm91030017

2023-05-19

Advances in respiratory medicine

Abstract:Lung ultrasound has become a part of the daily examination of physicians working in intensive, sub-intensive, and general medical wards. The easy access to hand-held ultrasound machines in wards where they were not available in the past facilitated the widespread use of ultrasound, both for clinical examination and as a guide to procedures; among point-of-care ultrasound techniques, the lung ultrasound saw the greatest spread in the last decade. The COVID-19 pandemic has given a boost to the use of ultrasound since it allows to obtain a wide range of clinical information with a bedside, not harmful, repeatable examination that is reliable. This led to the remarkable growth of publications on lung ultrasounds. The first part of this narrative review aims to discuss basic aspects of lung ultrasounds, from the machine setting, probe choice, and standard examination to signs and semiotics for qualitative and quantitative lung ultrasound interpretation. The second part focuses on how to use lung ultrasound to answer specific clinical questions in critical care units and in emergency departments.

Book review: Acute respiratory distress syndrome - a comprehensive clinical approach

Acute lung injury and the acute respiratory distress syndrome: a clinical review

Acute respiratory distress syndrome: A review of ARDS across the life course

Acute Respiratory Distress Syndrome: Bench‐to‐Bedside Approaches to Improve Drug Development

The Acute Respiratory Distress Syndrome in 2013

Acute Respiratory Distress Syndrome: Bench-to-Bedside Approaches to Improve Drug Development.

Towards Simulation-Based Similarity of End User Browsing Processes

[Consensus conference: home intravenous antibiotic treatment for cystic fibrosis. The Sira Carrasco Foundation. 26 April 2002].

ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies

Acute Respiratory Distress Syndrome and COVID-19: A Literature Review

An Overview on Mechanistic Insights and Clinical Benefit

Lymphocytic hypophysitis with normal pituitary function mimicking a pituitary adenoma: a case report and review of literature.

Early identification and diagnosis, pathophysiology, and treatment of sepsis-related acute lung injury: a narrative review

Definitions of Acute Respiratory Distress Syndrome: Present Recommendations and Challenges

Share First, Save Later: Performance of Self through Snapchat Stories

The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum.

Lung- and Diaphragm-protective Ventilation in Acute Respiratory Distress Syndrome: Rationale and Challenges.

Management of the acute respiratory distress syndrome

An Update on Management of Adult Patients with Acute Respiratory Distress Syndrome: An Official American Thoracic Society Clinical Practice Guideline

Monitoring Patient Respiratory Effort During Mechanical Ventilation: Lung and Diaphragm-Protective Ventilation

Lung Ultrasound in Critical Care and Emergency Medicine: Clinical Review